Duración del tratamiento con etanercept y razones de discontinuación en una cohorte de pacientes con patología reumática

Gallego, José; Salazar, José Rosas-Gómez de; Santos-Soler, G.; Santos-Ramírez, C.; Sánchez‐Barrioluengo, Mabel; Salas-Heredia, Esteban; Barber, Xavier; Cano-Pérez, Catalina; Llahí-Vidal, Núria; Riestra-Juán, Rosa

doi:10.1016/j.reuma.2011.06.005

Cited by 7 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our group conducted an observational study comparing the duration of treatment with etanercept with that of the rest of the biologic drugs in our cohort of patients on biologic therapy 63. We included 205 patients on biologic treatment, 92 patients on treatment with etanercept, 33% of whom had AS.…”

Section: Safety Of Etanercept In Asmentioning

confidence: 99%

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Gallego¹,

Santos-Ramírez²,

Santos-Soler³

et al. 2013

PPA

Self Cite

View full text Add to dashboard Cite

To date, anti-tumor necrosis factor alfa (anti-TNF-α) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive efficacy and safety. Etanercept has demonstrated efficacy in the treatment of ankylosing spondylitis, with or without radiographic sacroiliitis, and other manifestations of the disease, including peripheral arthritis, enthesitis, and psoriasis. Etanercept is not efficacious in inflammatory bowel disease, and its efficacy in the treatment of uveitis appears to be lower than that of other anti-TNF drugs. Studies of etanercept confirmed regression of bone edema on magnetic resonance imaging of the spine and sacroiliac joint, but failed to reduce radiographic progression, as do the other anti-TNF drugs. It seems that a proportion of patients remain in disease remission when the etanercept dose is reduced or administration intervals are extended. Etanercept is generally well tolerated with an acceptable safety profile in the treatment of ankylosing spondylitis. The most common adverse effect of etanercept treatment is injection site reactions, which are generally self-limiting. Reactivation of tuberculosis, reactivation of hepatitis B virus infection, congestive heart failure, demyelinating neurologic disorders, hematologic disorders like aplastic anemia and pancytopenia, vasculitis, immunogenicity, and exacerbation or induction of psoriasis are class effects of all the anti-TNF drugs, and have been seen in patients with ankylosing spondylitis. However, etanercept is less likely to induce reactivation of tuberculosis than the other anti-TNF drugs and it has been suggested that etanercept might be less immunogenic, especially in ankylosing spondylitis. Acute uveitis, Crohn’s disease, and sarcoidosis are other adverse events that have been rarely associated with etanercept therapy in patients with ankylosing spondylitis.

show abstract

Section: Safety Of Etanercept In Asmentioning

confidence: 99%

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Gallego¹,

Santos-Ramírez²,

Santos-Soler³

et al. 2013

PPA

Self Cite

View full text Add to dashboard Cite

show abstract

“…These are lower most, and so perhaps only find out for the 1 st time after a medicine has already been made accessible for universal usage and enclose allergic reactions; examples anaphylaxis with penicillin or skin rashes with non-nucleoside reverse transcriptase inhibitors, and idiosyncratic reactions; instances bone marrow suppression of chloramphenicol; heparin induced thrombocytopenia. Type "B" Adverse drug reaction is slightly happened and cause great mortality, and also treated by stopping the administered medication [19,20].…”

Section: Classification Of Adrs According To Mechanism Of Originmentioning

confidence: 99%

Delineation and Classifications of Adverse Drug Reaction: Brief Communication

Bereda¹

2021

IJPC

View full text Add to dashboard Cite

Adverse drug reaction defined as reaction to medicine which is noxious and unintended and occurs at doses of medications normally used for prophylaxis, diagnosis, or treatment of disease or to change physiologic functions. Serious adverse effect defined as any unfavorable medical incidence that happens at any dose and results in death necessitates hospital admission or prolonged hospital stay, results in continuity or indispensable disability, or is life threatening. Type "A" adverse drug reaction is greatly happened and solely causes low mortality, and also treated by adjusting dose of the medication; for example toxic effects of alpha-adrenergic blockage side effects that is associated with tricyclic antidepressants; sexual dysfunction of selective serotonin reuptake inhibitors; ototoxicity from aminoglycosides toxicity; serotonin syndrome of monoamine oxidase inhibitors. Type "B" reactions signifies' (bizarre, idiosyncratic), unpredictable or non-pharmacological, frequently allergic, response reactions are novel responses that are not anticipated from the familiar pharmacological actions of the medication. Type "C" reactions signifies' 'continuing or long term (time related)' reactions, continue for a relatively long time and prolonged usage of medicine. Type "D" reactions signifies' delayed (lag time)' reactions, becomes presumed occasionally after the usage of a medication. Type "E" reactions signifies' 'ending-of-usage (withdrawal)' reactions, is associated with the withdrawal of a medication. For example is withdrawal syndrome with benzodiazepines; withdrawal syndrome with tricyclic antidepressants and the undesired effects of ceasing the drug (for example, rebound hypertension with beta blockers). Type "F" reactions signifies' unanticipated failure of therapy (no response). Where a medication unpleasantly escalates or de-escalates in efficacy, for examples, the de-escalated clearance of a medication by dialysis, or the de-escalated consequence of antimicrobials agents' particularly anti-tuberculosis medication resistance due to resistant organism.

show abstract

“…Socioeconomic factors have been studied across medical disciplines and can be related to either the patient or the caregiver. 15 – 20 Patient-related socioeconomic factors can result in poor understanding of the disease or its treatment, in support of belief in unvalidated, belief-based treatment approaches, and limited access to care or treatment. Understandably, the views and responses of caregivers to these various issues have a major influence on outcomes.…”

Section: Summary Of Therapeutic Options For Noninfectious Uveitismentioning

confidence: 99%

Noninfectious uveitis: strategies to optimize treatment compliance and adherence

Dolz-Marco¹,

Gallego-Pinazo²,

Díaz-Llopis³

et al. 2015

OPTH

View full text Add to dashboard Cite

Noninfectious uveitis includes a heterogenous group of sight-threatening ocular and systemic disorders. Significant progress has been made in the treatment of noninfectious uveitis in recent years, particularly with regard to the effective use of corticosteroids and non-corticosteroid immunosuppressive drugs, including biologic agents. All of these therapeutic approaches are limited, however, by any given patient’s ability to comply with and adhere to their prescribed treatment. In fact, compliance and adherence are among the most important patient-related determinants of treatment success. We discuss strategies to optimize compliance and adherence.

show abstract

Duración del tratamiento con etanercept y razones de discontinuación en una cohorte de pacientes con patología reumática

Cited by 7 publications

References 16 publications

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Delineation and Classifications of Adverse Drug Reaction: Brief Communication

Noninfectious uveitis: strategies to optimize treatment compliance and adherence

Contact Info

Product

Resources

About